[Clinical and ergometric studies on the effectiveness of lidoflazine in the treatment of chronic ischemic heart disease].
During 6 months lidoflazine was applied ambulatorily in a dosage of 240 mg/a day orally in 21 patients after finished infarction. After 2 to 3 weeks one patient each was excluded due to incompatibility or reinfarction, respectively. In the remaining 19 patients consumption of nitrangin, mechanocardiogram, ECG and blood pressure were controlled in regular intervals during and after ergometric load as well as clinico-chemical examinations performed. The consumption of nitrangin clearly decreased in the course of the time of observation. The tolerance ofthe medicament was good. At the end of the treatment the unchanging load was tolerated with lower pulse rate, slightly decreased blood pressure and shortened period of isometric contraciton and period of the increase of blood pressure. The present results were discussed compared with literature.
D000818:Animals; D001794:Blood Pressure; D002908:Chronic Disease; D003327:Coronary Disease / Q000188:drug therapy* / Q000503:physiopathology; D004285:Dogs; D004341:Drug Evaluation; D004361:Drug Tolerance; D005080:Exercise Test; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006261:Headache / Q000139:chemically induced; D006801:Humans; D008013:Lidoflazine / Q000009:adverse effects / Q000627:therapeutic use*; D010879:Piperazines / Q000627:therapeutic use*; D011674:Pulse; D014717:Vertigo / Q000139:chemically induced
D010879:Piperazines; D008013:Lidoflazine
Klinische und ergometrische Untersuchungen zur Wirksamkeit von Lidoflazin bei der Therapie der chronisch ischämischen Herzerkrankung